US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
pharma · Anemia · Anemia Associated With Chronic Kidney Disease · AKBA
Akebia Europe
Akebia Europe Limited
Akebia Europe drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2007 Founded
271 Employees
Public company Type
AKBA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2007
- Employees
- 271
- Programs
- 25
- Drugs
- 13
- Patents
- 28
Akebia Europe pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Akebia Europe drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Akebia Europe in public FDA and regional records.
-
epoetin alfa
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent
-
ferric citrate coordination complex
Various (V03)Various (V03) compound in Akebia Europe's portfolio. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent
-
Development asset linked to Akebia Europe in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Akebia Europe in public FDA and regional records.
-
Development asset linked to Akebia Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Egl nine homolog 1.
- Target
- Egl nine homolog 1
- Mechanism
- Egl nine homolog 3 inhibitor